These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 21150876)

  • 1. New pathophysiological insights and treatment of ANCA-associated vasculitis.
    Wilde B; van Paassen P; Witzke O; Tervaert JWC
    Kidney Int; 2011 Mar; 79(6):599-612. PubMed ID: 21150876
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New advances in the pathogenesis of ANCA-associated vasculitides.
    Chen M; Kallenberg CG
    Clin Exp Rheumatol; 2009; 27(1 Suppl 52):S108-14. PubMed ID: 19646356
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-neutrophil cytoplasmic antibody pathogenesis in small-vessel vasculitis: an update.
    Gómez-Puerta JA; Bosch X
    Am J Pathol; 2009 Nov; 175(5):1790-8. PubMed ID: 19815703
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pathogenesis of anti-neutrophil cytoplasmic antibody-associated vasculitis: challenges and solutions 2014.
    Schönermarck U; Csernok E; Gross WL
    Nephrol Dial Transplant; 2015 Apr; 30 Suppl 1():i46-52. PubMed ID: 25540095
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pathogenesis of ANCA-associated vasculitis: new possibilities for intervention.
    Kallenberg CG; Stegeman CA; Abdulahad WH; Heeringa P
    Am J Kidney Dis; 2013 Dec; 62(6):1176-87. PubMed ID: 23810690
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antineutrophil cytoplasmic antibody-associated vasculitides: is it time to split up the group?
    Millet A; Pederzoli-Ribeil M; Guillevin L; Witko-Sarsat V; Mouthon L
    Ann Rheum Dis; 2013 Aug; 72(8):1273-9. PubMed ID: 23606701
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ANCA-associated vasculitis: diagnostic and therapeutic strategy.
    Ozaki S
    Allergol Int; 2007 Jun; 56(2):87-96. PubMed ID: 17460438
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Republished: Antineutrophil cytoplasmic antibody-associated vasculitides: is it time to split up the group?
    Millet A; Pederzoli-Ribeil M; Guillevin L; Witko-Sarsat V; Mouthon L
    Postgrad Med J; 2014 May; 90(1063):290-6. PubMed ID: 24737903
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical and immunological features of drug-induced and infection-induced proteinase 3-antineutrophil cytoplasmic antibodies and myeloperoxidase-antineutrophil cytoplasmic antibodies and vasculitis.
    Csernok E; Lamprecht P; Gross WL
    Curr Opin Rheumatol; 2010 Jan; 22(1):43-8. PubMed ID: 19770659
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Emerging concepts in the pathogenesis of antineutrophil cytoplasmic antibody-associated vasculitis.
    Flint SM; McKinney EF; Smith KG
    Curr Opin Rheumatol; 2015 Mar; 27(2):197-203. PubMed ID: 25629443
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Update on clinical, pathophysiological and therapeutic aspects in ANCA-associated vasculitides.
    Lamprecht P; Holle J; Gross WL
    Curr Drug Discov Technol; 2009 Dec; 6(4):241-51. PubMed ID: 20025591
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ANCA-associated vasculitis.
    Kitching AR; Anders HJ; Basu N; Brouwer E; Gordon J; Jayne DR; Kullman J; Lyons PA; Merkel PA; Savage COS; Specks U; Kain R
    Nat Rev Dis Primers; 2020 Aug; 6(1):71. PubMed ID: 32855422
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pathogenesis of PR3-ANCA associated vasculitis.
    Kallenberg CG
    J Autoimmun; 2008; 30(1-2):29-36. PubMed ID: 18162369
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased levels of BLyS and sVCAM-1 in anti-neutrophil cytoplasmatic antibody (ANCA)-associated vasculitides (AAV).
    Schneeweis C; Rafalowicz M; Feist E; Buttgereit F; Rudolph PE; Burmester GR; Egerer K
    Clin Exp Rheumatol; 2010; 28(1 Suppl 57):62-6. PubMed ID: 20412705
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The future of ANCA-associated vasculitis.
    Holle JU; Wieczorek S; Gross WL
    Rheum Dis Clin North Am; 2010 Aug; 36(3):609-21. PubMed ID: 20688253
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [New aspects in ANCA-associated vasculitides].
    Lamprecht P
    Med Klin (Munich); 2004 Sep; 99(9):518-22. PubMed ID: 15372181
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current therapies for ANCA-associated vasculitis.
    Lally L; Spiera R
    Annu Rev Med; 2015; 66():227-40. PubMed ID: 25341007
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pathogenetic and Clinical Aspects of Anti-Neutrophil Cytoplasmic Autoantibody-Associated Vasculitides.
    Lamprecht P; Kerstein A; Klapa S; Schinke S; Karsten CM; Yu X; Ehlers M; Epplen JT; Holl-Ulrich K; Wiech T; Kalies K; Lange T; Laudien M; Laskay T; Gemoll T; Schumacher U; Ullrich S; Busch H; Ibrahim S; Fischer N; Hasselbacher K; Pries R; Petersen F; Weppner G; Manz R; Humrich JY; Nieberding R; Riemekasten G; Müller A
    Front Immunol; 2018; 9():680. PubMed ID: 29686675
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neutrophil Extracellular Traps in ANCA-Associated Vasculitis.
    Söderberg D; Segelmark M
    Front Immunol; 2016; 7():256. PubMed ID: 27446086
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis: advances in pathogenesis and treatment].
    Silva F; Cisternas M
    Rev Med Chil; 2013 Jun; 141(6):765-73. PubMed ID: 24121580
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.